**Core Concept**
The management of type 2 diabetes mellitus (T2DM) in obese patients involves selecting antidiabetic medications that are effective, safe, and suitable for weight management. The ideal medication should either promote weight loss or have a neutral effect on body weight.

**Why the Correct Answer is Right**
Metformin is the preferred initial pharmacotherapy for T2DM, especially in obese patients. It works by decreasing hepatic glucose production, improving insulin sensitivity, and promoting weight loss. Metformin's weight-neutral effect or even weight loss is beneficial for obese patients, making it an ideal choice. Metformin also has a low risk of hypoglycemia and does not cause weight gain, unlike some other antidiabetic medications.

**Why Each Wrong Option is Incorrect**
**Option A:** Thiazolidinediones (TZDs) are not the best choice for obese patients as they can cause weight gain and fluid retention. They also increase the risk of heart failure.
**Option B:** SGLT2 inhibitors can cause weight loss but may not be the first choice for obese patients due to concerns about genital infections and increased risk of amputations.
**Option C:** GLP-1 receptor agonists can promote weight loss but may not be the best initial choice for obese patients due to their higher cost and potential gastrointestinal side effects.

**Clinical Pearl / High-Yield Fact**
When initiating pharmacotherapy in obese T2DM patients, it's essential to choose medications that promote weight loss or are weight-neutral, such as metformin, to improve glycemic control and reduce the risk of cardiovascular complications.

**Correct Answer:** A. Metformin